- Aurinia Pharmaceuticals recently initiated PRESERVE, a Phase 4 multicenter US study evaluating LUPKYNIS in combination with belimumab, obinutuzumab or anifrolumab in approximately 150 lupus nephritis patients, with complete renal response at 6 months as the primary endpoint.
- This post-approval trial builds on LUPKYNIS’s status as the only FDA-approved oral therapy for lupus nephritis and the only treatment to show a statistically significant increase in complete renal response at 6 months, potentially broadening its role in combination regimens.
- We’ll now examine how this new Phase 4 combination study for LUPKYNIS may influence Aurinia’s investment narrative and future growth drivers.
The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
Aurinia Pharmaceuticals Investment Narrative Recap
To own Aurinia, you need to believe LUPKYNIS can sustain its position in lupus nephritis while management carefully manages concentration risk in a single commercial asset. The PRESERVE Phase 4 combination study reinforces LUPKYNIS’s clinical profile, but its near term effect on the key catalyst short term revenue and prescription trends appears limited, while dependence on one drug and ongoing exclusivity and Paragraph IV questions remain the central risk.
Among recent updates, the AURORA 1 Phase 3 data presented at EULAR 2026 looks most connected to PRESERVE. Those results, showing reduced renal related events and death in LUPKYNIS treated patients, strengthen the clinical rationale for testing combinations with belimumab, obinutuzumab, and anifrolumab. Together, AURORA 1 outcomes and PRESERVE could shape how durable LUPKYNIS’s role is in treatment algorithms, which matters for how investors think about future revenue resilience.
Yet in contrast to the bullish data points, investors should be aware that Aurinia’s reliance on a single marketed drug still leaves them exposed to...
Read the full narrative on Aurinia Pharmaceuticals (it's free!)
Aurinia Pharmaceuticals' narrative projects $461.3 million revenue and $176.3 million earnings by 2029. This requires 15.6% yearly revenue growth and a $121.9 million earnings decrease from $298.2 million today.
Uncover how Aurinia Pharmaceuticals' forecasts yield a $17.00 fair value, a 7% upside to its current price.
Exploring Other Perspectives
While PRESERVE could eventually support a more resilient LUPKYNIS story, the most pessimistic analysts were assuming revenue of about US$406.7 million and earnings of only US$62.7 million by 2029, so you may want to weigh that more cautious view against the combination data now emerging.
Explore 6 other fair value estimates on Aurinia Pharmaceuticals - why the stock might be worth just $17.00!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Aurinia Pharmaceuticals research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Aurinia Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Aurinia Pharmaceuticals' overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
Opportunities like this don't last. These are today's most promising picks. Check them out now:
- Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.
- Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
- This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com